

# CITATION REPORT

List of articles citing

Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity

DOI: 10.1177/0961203318768877

Lupus, 2018, 27, 1718-1722.

**Source:** <https://exaly.com/paper-pdf/68959564/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. <i>Current Opinion in Rheumatology</i> , <b>2018</b> , 30, 482-489	5.3	30
19	Novel paradigms in systemic lupus erythematosus. <i>Lancet, The</i> , <b>2019</b> , 393, 2344-2358	40	186
18	A review of the evidence and cost of therapies for cutaneous lupus erythematosus. <i>Lupus</i> , <b>2019</b> , 28, 799-805	1	1
17	Management of cutaneous manifestations of lupus erythematosus: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 95-127	5.3	18
16	Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. <i>Arthritis Care and Research</i> , <b>2020</b> , 72 Suppl 10, 27-46	4.7	7
15	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. <i>Rheumatology</i> , <b>2020</b> , 59, v69-v81	3.9	16
14	Cutaneous Lupus Erythematosus: Progress and Challenges. <i>Current Allergy and Asthma Reports</i> , <b>2020</b> , 20, 12	5.6	3
13	Dihydroartemisinin attenuated the symptoms of mice model of systemic lupus erythematosus by restoring the Treg/Th17 balance. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2021</b> , 48, 626-633	6	6
12	What's New in the Treatment of Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 655100	4.9	10
11	Editorial: Quinacrine: au Revoir or Adieu? This safe and effective drug should be reintroduced. <i>Current Opinion in Rheumatology</i> , <b>2021</b> , 33, 219-220	5.3	
10	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus - Part 2: Therapy, risk factors and other special topics. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 1371-1395	1.2	1
9	S2k-Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematosus - Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 1371-1395	1.2	0
8	Antimalarial drugs (and lupus). <b>2021</b> , 601-609		
7	Antiprotozoal agents: How have they changed over a decade?. <i>Archiv Der Pharmazie</i> , <b>2021</b> , e2100338	4.3	1
6	Tratamiento del lupus cutáneo con quinacrina: una serie de 6 casos. <i>Piel</i> , <b>2020</b> , 35, 278-279	0.1	
5	Tailored treatment strategies and future directions in systemic lupus erythematosus.. <i>Rheumatology International</i> , <b>2022</b> , 1	3.6	0
4	Diagnostik und Therapie des kutanen Lupus erythematosus [Aktuelles aus der S2k-Leitlinie. <i>Aktuelle Rheumatologie</i> ,	0.1	

3 Recent Advances in SLE Treatment Including Biologic Therapies.

2 Surveying Dermatologists prescribing of Mepacrine.

1 Manifestaciones cutáneas en pacientes con lupus eritematoso sistémico: formas al inicio de la enfermedad y durante el seguimiento. Análisis retrospectivo. **2023,**

0